AbbVie Acquires Apogee Therapeutics for $10.9 Billion in Eczema Drug Bet
AbbVie is paying $10.9B for Apogee Therapeutics, whose experimental atopic dermatitis drug sent shares surging nearly 47% Monday.
AbbVie announced Monday it will acquire Apogee Therapeutics in a deal valued at $10.9 billion, placing a massive wager on an experimental drug designed to treat atopic dermatitis, the chronic inflammatory skin condition commonly known as eczema. The acquisition signals AbbVie's continued drive to build out its immunology pipeline as it seeks to offset long-term revenue pressure from biosimilar competition against its blockbuster drug Humira.
Apogee Therapeutics shareholders reacted swiftly and decisively, with the biotech company's stock closing nearly 47% higher on Monday — a surge that reflected the substantial premium AbbVie was willing to pay to secure the promising therapy. The dramatic single-day gain underscores how aggressively large pharmaceutical players are competing for late-stage or emerging pipeline assets in dermatology and immunology, two of the most commercially lucrative therapeutic areas in the industry.
Read more SK Hynix Tops Samsung; Apple Warns of Imminent Price Hikes →
Atopic dermatitis affects millions of Americans and represents a crowded but high-value market, with existing treatments from rivals including Dupixent, jointly marketed by Sanofi and Regeneron, generating billions in annual sales. AbbVie's willingness to spend nearly $11 billion for access to an experimental candidate reflects both the commercial potential of the space and the company's urgency to secure next-generation assets before competitors do.
The deal is the latest in a string of large-scale biotech acquisitions by major pharmaceutical firms looking to replenish pipelines through M&A rather than solely through internal research and development. For Apogee, the acquisition represents a swift and lucrative outcome for a biotech that had been working to carve out a foothold in a fiercely contested therapeutic category.
Continue reading at MarketWatch.com
